Showing 1 - 4 results of 4 for search 'Pieter Pannus', query time: 0.02s Refine Results
  1. 1
    Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

    Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant by Kevin K. Ariën, Leo Heyndrickx, Johan Michiels, Katleen Vereecken, Kurt Van Lent, Sandra Coppens, Betty Willems, Pieter Pannus, Geert A. Martens, Marjan Van Esbroeck, Maria E. Goossens, Arnaud Marchant, Koen Bartholomeeusen, Isabelle Desombere

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.

    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens

    Published 2022-01-01
    Get full text
    Article
  3. 3
    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

    Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K. Ariën, Maria E. Goossens

    Published 2022-01-01
    Get full text
    Article
  4. 4
    Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors

    Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors by Angelina Konnova, Angelina Konnova, Fien H. R. De Winter, Akshita Gupta, Akshita Gupta, Lise Verbruggen, An Hotterbeekx, Matilda Berkell, Matilda Berkell, Laure-Anne Teuwen, Greetje Vanhoutte, Greetje Vanhoutte, Bart Peeters, Silke Raats, Isolde Van der Massen, Sven De Keersmaecker, Yana Debie, Yana Debie, Manon Huizing, Pieter Pannus, Kristof Y. Neven, Kristof Y. Neven, Kristof Y. Neven, Kevin K. Ariën, Kevin K. Ariën, Geert A. Martens, Marc Van Den Bulcke, Ella Roelant, Ella Roelant, Isabelle Desombere, Sébastien Anguille, Zwi Berneman, Zwi Berneman, Maria E. Goossens, Herman Goossens, Surbhi Malhotra-Kumar, Evelina Tacconelli, Timon Vandamme, Timon Vandamme, Marc Peeters, Marc Peeters, Peter van Dam, Peter van Dam, Samir Kumar-Singh, Samir Kumar-Singh

    Published 2022-12-01
    Get full text
    Article

Search Tools: